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Autònoma de Barcelona, Cerdanyola del Vallès, Spain; 3Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol,
Badalona, Spain; 4Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 5Faculty of Medicine,
University of Vic - Central University of Catalonia (UVic-UCC), Vic, Spain
*Corresponding author. E-mail: jgarciaprado@irsicaixa.es
Received 3 February 2020; returned 3 March 2020; revised 21 April 2020; accepted 3 May 2020
Background: Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the develop-
ment of resistance-associated mutations in the protease gene.
Methods: From a cohort of 520 HIV-infected subjects treated with lopinavir/ritonavir or darunavir/ritonavir
monotherapy, we retrospectively identified nine patients with VF. We sequenced the HIV-1 Gag-protease region
and generated clonal virus from plasma samples. We characterized phenotypically clonal variants in terms of
replicative capacity and susceptibility to PIs. Also, we used VESPA to identify signature mutations and 3D molecu-
lar modelling information to detect conformational changes in the Gag region.
Results: All subjects analysed harboured Gag-associated polymorphisms in the absence of resistance mutations
in the protease gene. Most Gag changes occurred outside Gag cleavage sites. VESPA analyses identified K95R
and R286K (P < 0.01) as signature mutations in Gag present at VF. In one out of four patients with clonal analysis
available, we identified clonal variants with high replicative capacity and 8- to 13-fold reduction in darunavir sus-
ceptibility. These clonal variants harboured K95R, R286K and additional mutations in Gag. Low susceptibility
to darunavir was dependent on the Gag sequence context. All other clonal variants analysed preserved drug sus-
ceptibility and virus replicative capacity.
Conclusions: Gag mutations may reduce darunavir susceptibility in the absence of protease mutations while
preserving viral fitness. This effect is Gag-sequence context dependent and may occur during boosted PI failure.
Introduction
The introduction of active combined ART (cART) has led to the ef-
fective control of viral replication in HIV-1-infected individuals.
Although integrase inhibitor-based cART treatments are currently
the most widely used first-line regimens, darunavir/ritonavir and
lopinavir/ritonavir are used in some simplification strategies and
low-income settings.1–5
Despite the high genetic barrier of PIs to resistance develop-
ment, the emergence of mutations at the active site of the prote-
ase leads to HIV-1 drug resistance and virological failure (VF).6–9
The main pathways of drug resistance to PIs are well defined.
They initiate with mutational changes in the active site of the viral
protease,10 followed by a step-wise accumulation of mutations
surrounding the active site,10–12 at cleavage sites13–15 and at non-
cleavage sites of the Gag-pol polyprotein,15–17 which compensate
for replication defects and increase phenotypic resistance. The
emergence of protease-associated mutations is usually observed
in patients who have experienced VF to unboosted or first-
generation boosted PIs.18,19 On the other hand, this rarely occurs
in patients experiencing VF to cART based on the most recently
developed boosted PIs as first-line regimens or in simplification
strategies.6,8,9 This observation raises questions about the mech-
anism leading to VF to boosted PIs. Although the answer remains
elusive, increasing evidence points to the role played by the pres-
ence of mutations outside of the protease and other unexplored
mechanisms of resistance.
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In general with regard to HIV-1 resistance to PIs, several studies
demonstrate the contribution of the Gag region to PI susceptibility
in the absence of drug resistance mutations in the protease.20–24
Mutations in and outside of Gag cleavage sites have been directly
involved in resistance to PIs.20,25,26 These data are also supported
by co-evolutionary studies by our group and others that highlight a
tight interdependence between Gag and protease during the de-
velopment of PI resistance.27,28 Similarly, a recent clinical study
revealed associations between the presence of baseline mutations
in Gag and gp41 with VF to PI-based regimens.29 Also, the
C-terminal region of gp41 has been previously associated with PI
resistance in the absence of HIV-1 resistance mutations in the pro-
tease.19 Taken together, these data support a multistep inhibitory
mechanism of PI action at various levels of the viral replication
cycle, indicating the complexity of the resistance mechanisms
underlying VF to PIs. In particular for HIV-1 resistance to PIs in
monotherapy, changes in Gag have been associated with treat-
ment failure to monotherapy in the MONARK and SARA trials.22,24
In addition, the baseline Gag sequence context in A, C and D sub-
types has been linked to differences in PI susceptibility during
monotherapy.30,31
With the aim of gaining new insights into the causes of VF to
boosted PIs, we identified nine HIV-1-infected patients who had
been receiving monotherapy with lopinavir/ritonavir or darunavir/
ritonavir as a maintenance regimen but had experienced VF. Gag-
protease genotyping revealed the absence of HIV-1 resistance
mutations in the protease. We then successfully generated Gag-
protease molecular clones in four patients and phenotypically
characterized viral variants in terms of replicative capacity and
drug susceptibility to lopinavir and darunavir. Moreover, to shed
further light on the protein conformational changes present in clo-
nal variants, we used 3D information on Gag p17 and p24 crystal
structures.
Patients and methods
Study subjects
We performed a retrospective search among the 520 HIV-1-infected indi-
viduals who had been treated with lopinavir/ritonavir or darunavir/ritonavir
monotherapy in a clinical setting between 2002 and 2009 at the Germans
Trias i Pujol Hospital, to identify those who had experienced VF during
treatment and for whom stored plasma samples existed. VF was defined
as two consecutive viral loads of >50 HIV-RNA copies/mL during PI mono-
therapy. The search yielded nine patients, who had sustained virological
suppression (<50 HIV-RNA copies/mL) for at least 6 months before the
initiation of monotherapy and had recorded no VF to previous treatments
containing PIs.
Ethics statement
All subjects provided their written informed consent for the purpose of re-
search on biological samples taken from them. The project was approved
by the institutional review board of Germans Trias i Pujol Hospital (PI-19-
028). The study was conducted in accordance with the principles expressed
in the Declaration of Helsinki.
Amplification of the HIV-1 Gag-protease coding region
Total HIV-RNA was extracted, reverse-transcribed and amplified by a se-
cond polymerization step as previously described.27 Samples below 100
HIV-RNA copies/mL were ultracentrifuged at 72000 g for 90 min at 4C
Construction of HIV-1 Gag-protease recombinant virus
We used pNL43CXS and p83-2 vectors to generate p83-2DGP. We digested
these vectors with BssHII and AgeI (Thermo Fisher Scientific, Spain) at
unique restriction sites and the Gag-integrase region from pNL43CXS was
subcloned into p83-2. Then, the generated plasmid was digested with
BssHII and ClaI (Thermo Fisher Scientific, Spain) to remove the Gag-
protease region. Finally, we cloned a polylinker with BssHII, EcoRI, AgeI,
HindIII and ClaI restriction sites to obtain the p83-2DGP vector. Then, Gag-
protease regions were subcloned into p83-2DGP and the insert was identi-
fied by EcoRI digestion (Thermo Fisher Scientific, Spain) and subsequent
sequencing. Viral stocks were generated by transfection and viral spread
was monitored by determining the frequency of GFP-positive (GFP!) cells
as previously described.32 Supernatants were collected, filtered and stored
at #80C for further experiments. TCID50 was determined as previously
described.33
Sequence analyses and viral epidemiology signature
analyses
All positive PCR reactions and recombinant clones were sequenced using
the Sanger reaction (Macrogene, Netherlands). Sequences were aligned to
the HXB2 sequence, and analysed using the neighbour-joining phylogenetic
method as previously described.27 We used the Stanford University HIV
Drug Resistance Database for drug resistance interpretation.34 In addition,
we used Los Alamos National Laboratory’s Viral Epidemiology Signature
Pattern Analysis (VESPA) tool to identify signature mutations in the Gag
coding region associated with VF to boosted PI therapy.35 The VESPA tool
calculates the frequency of each amino acid at each position of the align-
ment for the query (boosted PI in VF sequences) and the background set
(treatment-naive B-clade sequences), and selects the position of the most
common character in the query that differs from the background set. We
retrieved 2757 treatment-naive B-clade Gag sequences from the Los
Alamos database and excluded duplicated sequences using the ElimDupes
tool. Sequences were then imported to VESPA and compared with the Gag
bulk sequences obtained during VF to boosted PIs.35
Replication kinetics and drug susceptibility to PIs of
Gag-protease recombinant virus
Jurkat cells (National Institutes of Health, USA) were infected with the WT
virus or the Gag-protease recombinant virus in triplicate at an moi of 0.005.
Cells were washed with PBS once, cultured in R10 (0.5%106 cells/mL) and
GFP! cells were monitored over 12 days as previously described.32 The
growth rate was calculated as the slope of GFP! cells during exponential
growth.33,36 In addition, we measured virus susceptibility in the presence of
0.01, 1 and 100 nM of darunavir and lopinavir and GFP! cells were moni-
tored on days 1, 3, 6 and 10.37 The fold change in darunavir and lopinavir
was calculated as the ratio of GFP! cells between the recombinant and WT
virus during exponential growth.
Molecular modelling
Protein structures of p24 (PDB 1E6J) and p17 trimer (PDB 1HIW) were
obtained from RCSB PDB.38 The structures represent the B-clade virus and
were modified using the PyMOL Molecular Graphics System, Version 1.8
(Schrödinger, New York, USA).
Results
Gag polymorphisms are predominant during VF to
boosted PIs
As noted, out of 520 subjects treated with lopinavir/ritonavir or
darunavir/ritonavir as a maintenance regimen, we identified nine
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patients (1.7%) who fulfilled the inclusion criteria. Their baseline
epidemiological and clinical characteristics are summarized in
Table 1 and clinical follow-up and sampling are represented in
Figure 1. Cross-sectional plasma samples (T1) were available at VF
from Patients 1–9 (PT1–PT9) and longitudinal samples (T2) were
available from PT3 and PT4. A total of nine samples from seven
patients were successfully amplified for the Gag-protease HIV-1
coding region by RT-PCR as represented in the flow chart in
Figure 2.
The amplified Gag-protease sequences confirmed B-clade sub-
types and protease genotypes fully susceptible to lopinavir and
darunavir at VF.34 Protease genotypes are summarized in Table 2.
Only non-polymorphic and polymorphic PI accessory selected
mutations were found in PT1 (K20T), PT4 (A71V) and PT5 (L10V).
Genotypes of the Gag region at cleavage site (CS) and non-
cleavage site (NCS) mutations are summarized in Table 3. We cal-
culated the frequency of mutations in the Gag proteins as the me-
dian of the number of mutations in relation to the total length of
the protein in amino acids. The frequency of CS mutations ranged
Table 1. Epidemiological and baseline characteristics of the study group
Characteristic Study group (n = 9)
Male gender, n (%) 8 (88.9)
Caucasian origin [n (%)] 9 (100)
Age (years), median (range) 46 (33–56)
Nadir CD4! T-cell count per mm3,
median (IQR)
226.3 (14–397)
Time since diagnosis of HIV-1
(years), median (IQR)
8.45 (1.47–17.21)
Time on cART (years), median (IQR) 7.25 (0.1–17)
Time with virological suppression
after PI monotherapy initiation
(months), median (IQR)
20.27 (44–6)
Therapy on simplification
lopinavir/ritonavir, n (%) 6 (66.7)
darunavir/ritonavir, n (%) 3 (33.3)
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Figure 1. Clinical follow-up and sampling of study subjects. Blue lines indicate CD4! T-cell counts (cells/mm3) and red lines the HIV-1 viral load (RNA
copies/mL) during follow-up after boosted PI monotherapy initiation. Arrows indicate samples analysed at corresponding timepoints (T1 and T2).
This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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from 0% in p24 to 7.14% in p2. We found Gag CS mutations associ-
ated with PI exposure in vivo at p2/p7, p7/p1 and p1/p6 in most of
the patients (Table 3). At p2/p7, we found the mutation S373P in
PT2 and PT6, the mutation A374S/P in PT3 and PT5 and the muta-
tion T375A in PT4. Also, we identified changes in p7/p1 at K436R
and I437V positions, respectively, in PT5 and PT7. In PT4, a single
CS mutation was found at position S451N of p1/p6. For NCS muta-
tions, the frequency of variations was 7.57% in p17, 3.47% in p24,
7.14% in p2, 3.63% in p7, 9.6% in p6 and 0% in p1. The frequency
of NCS mutations correlated with the total frequency of amino
acid variation in Gag (P < 0.0001; r = 0.83, Spearman correlation,
data not shown). We observed Gag NCS mutations previously
associated with exposure or resistance to PIs. The R76K mutation
was present in 57% of the cases of VF and the E12K/D mutation
was present in PT2, PT5 and PT6. Also, we found NCS mutations at
positions V370A/M in p2 (PT3, PT5 and PT6) and I389T in p7 (PT2,
PT3, PT4, PT5 and PT6). Other changes including CS and NCS muta-
tions with unknown impact on drug resistance are also summar-
ized in Table 3. These data indicate a relative predominance of Gag
NCS mutations and an absence of protease resistance mutations
during VF to lopinavir/ritonavir or darunavir/ritonavir.
Gag signature patterns during VF to boosted PIs
Next, we applied VESPA to identify Gag residues correlated with VF
to boosted PIs in our sequences. VESPA compared the frequency of
each Gag amino acid between our nine Gag bulk sequences with
the background alignment of 2000 HIV-1 subtype B Gag sequen-
ces. As a result, two variations in Gag were noted. At position 95 in
p17, we found K95R present in 44% of PI-treated patients at VF in
comparison with 12% of naive sequences (P < 0.01). At position
286 in p24, we identified the mutation R286K with a frequency of
78% in PI-treated patients and 35.5% in naive sequences
(P < 0.01). Thus, VESPA provided the signature K95R and R286K in
Gag.
Preserved replication kinetics of Gag-protease recom-
binant virus at VF
To further evaluate the phenotypic characteristics of the HIV-1 var-
iants during VF, we cloned the Gag-protease region into a p83-
2DGP as detailed above. We obtained Gag-protease clonal plas-
mids from four patients: PT1 (n = 10), PT3 (T1, n = 10), PT3
(T2, n = 8), PT4 (T1, n = 2), PT4 (T2, n = 3) and PT6 (n = 2). The low
viral loads may have limited the number of clones obtained at
VF. Phylogenetic analyses confirmed sequence identity and
lack of sample cross-contamination (Figure S1, available as
Supplementary data at JAC Online). We observed low clonal diver-
sity that is indicative of limited viral evolution during VF. In the case
of PT3, we were able to detect a cluster of clonal sequences [C5,
C6, C8 and C10 (Figure S1B)] containing drug resistance mutations
I52V and V82A in the protease at T2. Clonal sequences were also
analysed using the Stanford HIVdb database,34 and clones were
predicted to be PI susceptible, except the clones containing I52V
and V82A, which were predicted to have intermediate resistance
to lopinavir and be fully susceptibility to darunavir.
Viral stocks of Gag-protease clones were produced by co-
transfection and replication kinetics were monitored as shown in
Figure 3(a). Also, Table 4 summarizes in detail the genotypes of the
Table 2. Protease genotype in bulk sequences
Patient Timepoint cART VL (copies/mL)
Protease genotype
DRM polymorphisma
PT1 T1 LPV/r 340 – K20T, R41K, H69R, V77I
PT2 T1 LPV/r 3800 – R57K, L63P, E65D, V77I, I93L
PT3 T1 LPV/r 220 – I15V, R41K, E53D, R57K, I62V, L63P
T2 LPV/r 760 – I15V, R41K, E53D, R57K, I62V, L63P
PT4 T1 DRV/r 78 – E35D, N37T, L63P
T2 DRV/r 47 – E35D, N37H, R41K, I62V, L63P, A71V, I93L
PT5 T1 DRV/r 200 – L10V, L63P, I93L
PT6 T1 LPV/r 80 – N37S, I64V
PT7 T1 DRV/r 61 – I15V, M36I, N37D
DRM, drug resistance mutation.
aPolymorphisms shown in bold are based on the Stanford HIVdb genotype–phenotype tool.34
Patients on LPV/r or DRV/r monotherapy
(n= 520)
No-VF (n= 511)
VF (n= 9)
Patients with cross-sectional samples at
VF (n= 7)
Patients with longitudinal samples at VF
(n = 2)
Plasma samples in T1
(n= 7)
Plasma samples in T1 and T2
(n= 4)
Gag-protease successful amplifications
(n= 5)
Failed amplification
(n= 2)
Gag-protease successful amplifications
(n= 4)
Figure 2. Flow chart of study subject identification, available plasma
samples and successful Gag-protease amplifications.
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Gag-protease clonal virus tested. Most of the Gag-protease re-
combinant viruses did not show differences in replication kinetics
compared with the WT (Figure 3b). A subgroup of viruses from T1
showed an increment in viral replication (PT3 and PT6; P < 0.005),
and only one had a significant reduction (PT1; P < 0.0005) when
compared with the WT. Moreover, in PT3 and PT4 with longitu-
dinal clonal virus, we found a mixture of variants with preserved
and low viral replication (Figure 3b). Of note, for PT4 only
three mutational changes in Gag (E107G, T280A and E461G)
differentiated the high and the low replicative variants at T2
(Table 4). Overall, these results suggest a general preservation of
replicative capacity in the HIV-1 variants present at VF to lopina-
vir/ritonavir and darunavir/ritonavir.
Gag mutations alone reduce susceptibility to darunavir
Next, we tested drug susceptibility at increasing concentrations of
darunavir or lopinavir (0.01, 1 and 100 nM). As shown in Figure 4(a),
recombinant viruses from PT1, PT3 and PT6 were fully susceptible
to darunavir in accordance with the high genetic barrier of the
drug, even in the presence of I54V and V82A protease mutations,
as predicted by Stanford for the T2 clonal viruses 5 and 8 from
100 PT1
WT
WT
T1C1
WT
T1C6
T1C7
T1C11
T2C2
T2C10
T1C1
WT
T1C1
T2C2
T2C5
T2C8
PT3
PT4 PT6
10
1
%
 G
FP
+v
e 
ce
lls
0.1
0.01
100
10
1
%
 G
FP
+v
e 
ce
lls
0.1
0.01
0.5
***
**
*** ***
**
***
*** **
0.4
0.3
G
ro
w
th
 ra
te
 (s
lo
pe
 in
 J
K 
ce
lls
)
0.2
0.1
0
W
T
T1
C1
T1
C1
T2
C2
T2
C5
T2
C8
T1
C1
T1
C1
1
T2
C2
T2
C1
0
T1
C6
T1
C7
100
10
1
%
 G
FP
+v
e 
ce
lls
0.1
0.01
0 2 4 6
Days post-infection
8 10 12
0 2 4 6
Days post-infection
8 10 12 0 2 4 6
Days post-infection
8 10
PT1
PT3
PT4
PT6
12
0 2 4 6
Days post-infection
8 10 12
100
10
1
%
 G
FP
+v
e 
ce
lls
0.1
0.01
(a)
(b)
Figure 3. Replicative capacity of Gag-protease recombinant virus. (a) Replication kinetics of Gag-protease recombinant virus obtained from plasma
samples from PT1, PT3, PT4 and PT6. Jurkat (JK) cells were infected in triplicate at an moi of 0.005. The kinetics of replication were monitored as the
frequency of GFP! cells by flow cytometry. Black circles represent the WT virus, coloured circles denote T1 virus and coloured triangles represent virus
at T2. (b) The bar graph represents the growth rate of the virus calculated as the slope of GFP! cells during the replication kinetics experiments. Bars
represent the mean ± SD of three experimental replicates. The P values indicate comparisons between the recombinants and the WT virus. Only sig-
nificant P values (**P < 0.005, ***P < 0.0005) are represented. This figure appears in colour in the online version of JAC and in black and white in the
print version of JAC.
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PT3.34 Similarly, viruses from PT1, PT3 and PT6 were fully suscep-
tible to lopinavir with the exception of the clonal viruses 5 and 8
from PT3 at T2 (Table 4), which carry I54V and V82A protease
mutations able to replicate at 100 nM lopinavir (Figure 4b). In con-
trast, viruses from PT4 T1C1, T1C11 and T2C2 revealed low suscep-
tibility to darunavir with a median of 9.6-, 6.7- and 13.58-fold
increases in infectivity compared with the WT at 1 nM (Figure 4a).
Concomitantly, the virus PT4 T2C2 had a median increase of 4.43-
fold with 1 nM lopinavir, indicating a potential phenotype of daru-
navir and lopinavir cross-resistance. Replication kinetics in the
presence of 1 nM darunavir for viruses T1C1, T1C11 and T2C2 from
PT4 showed high replication and a significant increase in viral
growth compared with the WT (Figure 4c, d). Sequences of T1C1,
T1C11 and T2C2 from PT4 revealed identity in the Gag-protease
genotype as shown in Table 4. Mutations R76K in p17, T375A in p2/
p7 and S451N in p1/p6 were present, and have been previously
associated with exposure to PIs in vivo but not directly with drug re-
sistance to darunavir. Moreover, we observed three additional
amino acid differences (E107G in p17, T280A in p24 and E461G in
p6) in the low-replicating susceptible variant T2C10 from PT4
(Table 4). These data suggest sequence context dependency of
Gag for darunavir resistance.
To further understand the nature of Gag mutational changes in
clonal virus with low susceptibility to darunavir, we mapped the
observed Gag mutational changes in solved p17 and p24 crystal
structures. As shown in Figure 5, we mapped eight residues in p17
and three residues in p24. In p17, the residues were distributed at
positions K28Q, E55G, G62E, R76K, R91K, E93D, K95R and K113Q
(Figure 5a). Mutations were located between helix 1/2 (K28Q) and
the globular domain of helix 3 (E55G, G62E), which are essential for
protein structural stability and interactions with helix 4 (R76K) of
p17. Also, we found variations at the helix 4/5 flap region (R91K,
E93D and K95R) and helix 5 (K113Q). In p24, we mapped muta-
tional changes at helix 7 (L268M), at the linker between helix 7 and
8 (R268K) and at the helix 9/10 flap region (A326S) (Figure 5b). Of
note, all the darunavir-resistant clonal variants harboured the
K95R and R268K signature mutations identified by VESPA and both
positions are involved in structural flexibility of p17 and p24 tertiary
structures. Altogether, these data suggest that susceptibility to
darunavir can be affected by Gag mutations alone that have no
impact on viral replication.
Discussion
The efficacy and safety of boosted PI-containing regimens sup-
ports their clinical use worldwide. However, the mechanism of
virological escape from PI-based regimens remains not fully
understood. In fact, the VF to boosted PIs occurs in most cases in
the absence of drug resistance mutations in the protease.
The emergence of mutations outside protease has been exten-
sively described as one possible cause of this failure to boosted
PIs.20–26,39 These studies support the contribution of Gag and gp41
mutations in HIV-1 resistance to PIs21,29,40 and underpin
the complexity of the mechanisms that cause resistance.
Nevertheless, the lack of protease resistance mutations leads to dif-
ficult clinical decisions, particularly in low income resource settings,
where PIs are the second-line regimens recommended by the WHO.
Here, we focus on a homogeneous group of cART-experienced
B-clade HIV-1-infected individuals with lopinavir/ritonavir orTa
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darunavir/ritonavir monotherapy who experienced VF. This design
contrasts with previous studies that mainly focused on cART-naive
individuals with a diversity of HIV-1 subtypes.18,22,30 In this way,
we avoid confounding effects due to cART or viral subtype.
Moreover, we performed a detailed phenotypic analysis of clonally
co-evolved Gag-protease viruses in terms of viral replication and
drug susceptibility. Thus, our study provides novel insights on Gag
signature mutations and phenotypic pathways towards VF to
boosted PIs in the absence of protease drug resistance mutations.
Our findings agree with previous studies as we did not find drug
resistance-associated mutations in the protease during
VF.16,25,26,39,41 Regarding Gag sequences, we observed changes in
the CS, but predominantly in NCS locations. These data support our
previous findings of the predominance of Gag NCS mutations dur-
ing Gag-protease co-evolution.27 The mutations in Gag CS and NCS
are likely polymorphic changes relative to the consensus sequence
in the absence of baseline sequences for each patient that could
identify mutations within a patient over time.
At the CS, we observed mutations previously associated with
exposure to PIs.26,42–44 We observed mutations in p2/p7 (S373P,
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Figure 4. Drug susceptibility to lopinavir and darunavir of Gag-protease recombinant virus. (a) Fold change in darunavir (DRV) or (b) lopinavir (LPV).
Jurkat (JK) cells were incubated with 0.01, 1 and 100 nM of darunavir or lopinavir for 4 h prior to infection with the Gag-protease recombinant virus.
The fold change was calculated as the ratio between the percentage of GFP! cells in the Gag-protease recombinant virus and the percentage of
GFP! cells at Day 6 after infection. Bars represent the mean ± SD of three experimental replicates. (c) Replication kinetics of PT4 Gag-protease recom-
binant virus in the presence of 1 nM of darunavir in Jurkat cells over 10 days in culture. (d) Bar graph representing the growth rate of WT and PT4 re-
combinant variants calculated as the slope of GFP-expressing cells by FACS during the replication kinetics experiments in the presence of 1 nM of
darunavir. Bars represent the mean ± SD of three experimental replicates. The P values indicate comparisons of the recombinants with the WT. Only
significant P values (*P < 0.05, **P < 0.005, ***P<0.0005) are represented. This figure appears in colour in the online version of JAC and in black and
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Figure 5. Gag protein structural mapping. Solved crystal structure of p17
(a) and p24 (b). The green spheres indicate positions with changes when
compared with HXB2, whereas changes present only in T2C10 are indi-
cated by cyan spheres. This figure appears in colour in the online version
of JAC and in black and white in the print version of JAC.
Gag mutations reduce darunavir susceptibility JAC
2543
A374S/P and T375A). S373P has been associated with a weaker
virological response to saquinavir/ritonavir42,43 and A374S/P and
T375A have been found at increased frequency in PI-experienced
individuals.40 Also, we observed in p7/p1 the mutations K436R and
I437V, both of which have been associated with PI exposure in vivo
and in vitro and PI resistance in the absence of protease drug re-
sistance mutations.20,45 Moreover, in p1/p6 we identified S451N,
which has been previously associated with PI exposure in non-B
clade HIV-1 subtypes.30,41 In addition, at NCS locations we found
changes mainly in p17 (E12K, R76K and T81A), p2 (V370 A/M) and
p7 (I389T) previously associated with resistance to PIs.16,25,26,41,46
The R76K mutation has been previously associated with changes
in viral fitness and susceptibility to PIs but always in the context
of highly resistant HIV-1 proteases.25,39 The E12K/D mutation
has been previously detected in vitro during selection experiments
with amprenavir in the presence of additional PI resistance
mutations.16,46
Moreover, we identified two signature mutations (K95R in p17
and R286K in p24) in Gag NCS that were enriched in boosted
PI-treated subjects during VF according to VESPA analyses. The
R286K mutation has been recently described as an emerging
mutation in two patients infected with the HIV-1 recombinant
CRF02_AG during VF to darunavir.47 The identification of K95R and
R286K should be further confirmed in a larger number of sequen-
ces, but it could potentially help to classify patients with VF to
boosted PI. However, we need to emphasize that our study group
was receiving PI monotherapy, and this particular drug pressure
may lead to a specific resistance profile.
In this study, we obtained 11 clonally co-evolved Gag-protease
viruses across four patients and time. The low number of clones
obtained may be associated with the low levels of viral load at VF.
Phylogenetic analyses of clonal sequences identified low intrapa-
tient diversity and close sequence identity to the bulk sequences.
In addition, we detected a small cluster of sequences from PT3 at
T2 with mutations I54V and V82A in the protease, which have
previously been associated with the loss of viral fitness.44,48,49
However, the contribution of these clonal variants to VF is limited
based on the phenotypic information obtained.
In terms of functional characterization, the majority of clonal
viruses demonstrated a conserved replicative capacity and full sus-
ceptibility to darunavir or lopinavir. Therefore, most of the variants
at VF conserve the susceptibility to lopinavir and darunavir. In this
scenario, we propose that Gag mutations favour protein structural
changes in the absence of fitness cost and predispose to the devel-
opment of resistance to PIs.
Furthermore, we identified one out of four patients with clonally
co-evolved Gag-protease variants with high fitness and low sus-
ceptibility to darunavir. This is the first study to our knowledge
reporting changes in darunavir susceptibility caused by a Gag
effect alone. The low-susceptibility clones displayed total clonal
identity in the Gag-protease region, differing by only three amino
acid residues in Gag between the resistant and susceptible var-
iants, thus indicating the importance of the Gag sequence context
in the development of low susceptibility to darunavir, together
with a fitness advantage for evolution towards resistance. Previous
data support the accumulation of mutations in Gag with low
fitness cost as a factor contributing to acquired PI resistance.39
Our observation of these viruses with low impact on viral repli-
cation and low susceptibility to darunavir agrees with the
molecular modelling of p17 and p24 crystal structures. This model
suggests an increase in protein flexibility mediated by K95R and
R286K signature Gag mutations. We hypothesize that mutational
changes in Gag present at VF are associated with protein flexibility
and allow the preservation of viral replication while favouring
accessibility for the cleavage of Gag or incorporation of env as
previously suggested.28,50
Our results have some limitations. First, our data came
from observations of bulk Gag-protease sequences with a scant
follow-up over time and a limited number of clonal sequences.
Next-generation sequencing data may provide additional informa-
tion on the presence of minority resistance variants. However, lim-
ited sample availability, long periods between sample collection
and testing and VLs <200 copies/mL at VF reduced the feasibility
of this approach in our study.51–53 Second, we did not directly
evaluate the contribution of HIV-1 env as an alternative mechan-
ism to modulate PI resistance in combination with Gag.21,27–29
In summary, our study provides for the first time evidence that
mutational changes in Gag alone can reduce susceptibility to daru-
navir while preserving viral fitness. Signature mutations (K95R and
R286K) in Gag may be crucial for the development of VF to boosted
PIs. However, future site-directed mutagenesis and phenotypic
analyses are needed to clarify the specific contributions of K95R
and R286K to viral replication and darunavir susceptibility. The
identification of signature mutations in Gag and their implication in
darunavir resistance will be key to the improvement of patient
classification for clinical decisions after VF in order to prevent the
appearance of resistant variants or favour the reintroduction of
PIs. Our findings may be particularly relevant in low-income
settings where VF to second-line boosted PI-based regimens limits
future therapeutic options.
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